To the Editor: Bradbury et al. (Sept. 2 issue)(1) designed the randomized, open-label FLIGHT trial to test the efficacy of mycophenolate mofetil plus glucocorticoids as compared with glucocorticoids alone in patients with immune thrombocytopenia (ITP). The authors conclude that mycophenolate mofetil plus glucocorticoids is a promising treatment. In previous studies, we have found that patients with ITP have a higher prevalence of other autoimmune diseases, such as systemic lupus erythematosus and Sjogren's syndrome.(2,3) We wonder whether some patients in the FLIGHT trial might have had subclinical autoimmune diseases, not only ITP. Before we generalize the results of this trial to . . .
